EC Paediatrics

Clinical depression is a complex and multifaceted disorder intricately linked to the dysregulation of various neurotransmitters and their associated receptors in the central nervous system. The primary neurotransmitters implicated in the pathophysiology of depression include serotonin (5-HT), norepinephrine (NE), and dopamine (DA), each playing a pivotal role in mood regulation and overall affective states. Extensive research suggests that disruptions in the balance and signaling of these neurotransmitters contribute significantly to depressive symptoms [1,2].

1. Briley M and Chantal Md. “The importance of norepinephrine in depression”. Neuropsychiatric Disease and Treatment1 (2011): 9-13.
2. Rahmawati NA., et al. “Inflammation in depression”. Jurnal Psikiatri Surabaya2 (2021): 50.
3. Zhang P. “How can we use neurotransmitters in emotion and reward system to study depression?”. LIFE: International Journal of Health and Life-Sciences3 (2019): 41-62.
4. Thase ME. “The role of neurobiologic processes in treating depression”. The Journal of Clinical Psychiatry 10 (2010): e28.
5. Bymaster FP., et al. “New approaches to developing antidepressants by enhancing monoaminergic neurotransmission”. Expert Opinion on Investigational Drugs4 (2003): 531-543.
6. Şahin C., et al. “The neuroinflammation perspective of depression: reuniting the outstanding mechanisms of the pathophysiology”. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology2 (2016): 196-206.
7. Felger JC and Lotrich F. “Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications”. Neuroscience 246 (2013): 199-229.
8. Joca SR., et al. “Atypical neurotransmitters and the neurobiology of depression”. CNS and Neurological Disorders - Drug Targets, 8 (2015): 1001-1011.
9. Suneson K., et al. “Inflammatory depression—mechanisms and non-pharmacological interventions”. International Journal of Molecular Sciences4 (2021): 1640.
10. Pittenger C., et al. “The nmda receptor as a therapeutic target in major depressive disorder”. CNS and Neurological Disorders - Drug Targets2 (2007): 101-115.
11. Doshi G., et al. “Importance of exploring n-methyl-d-aspartate (nmda) as a future perspective target in depression”. CNS and Neurological Disorders - Drug Targets10 (2022): 1004-1016.
12. Wei S., et al. “Social defeat stress before pregnancy induces depressive-like behaviours and cognitive deficits in adult male offspring: correlation with neurobiological changes”. BMC Neuroscience1 (2018): 61.
13. Wong AH and Liu F. “Uncoupling the dopamine d1–d2 receptor complex: a novel target for antidepressant treatment”. Clinical Pharmacology and Therapeutics 2 (2011): 298-302.
14. Arango V. “Serotonin 1a receptors, serotonin transporter binding and serotonin transporter mrna expression in the brainstem of depressed suicide victims”. Neuropsychopharmacology6 (2001): 892-903.
15. Dawson LA and Bromidge SM. “5-ht1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders”. Current Topics in Medicinal Chemistry12 (2008): 1008-1023.
16. Chávez-Castillo M., et al. “Depression as a neuroendocrine disorder: emerging neuropsychopharmacological approaches beyond monoamines”. Advances in Pharmacological Sciences (2019): 1-20.
17. Utge S., et al. “Shared genetic background for regulation of mood and sleep: association of gria3 with sleep duration in healthy finnish women”. Sleep 10 (2011): 1309-1316.